Detalles de la búsqueda
1.
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
Blood
; 142(13): 1131-1142, 2023 09 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37363833
2.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 25(6): 744-759, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38821083
3.
Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia.
Vaccines (Basel)
; 11(7)2023 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37515017
4.
Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
Leuk Lymphoma
; 63(10): 2276-2289, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35737364
5.
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Lancet Haematol
; 9(3): e190-e199, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35240075
6.
Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands.
Clin Lymphoma Myeloma Leuk
; 18(1): 52-57, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29097160
7.
Prognostic factors in patients with breast cancer and malignant pleural effusion.
Breast J
; 16(6): 675-7, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21070453
8.
HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma.
Hemasphere
; 4(1): e325, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32072141
Resultados
1 -
8
de 8
1
Próxima >
>>